FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092114535> ?p ?o ?g. }

• W2092114535 endingPage "298" @default.
• W2092114535 startingPage "288" @default.
• W2092114535 abstract "Zoledronic acid (ZOL) reduces the risk of skeletal related events (SREs) in hormone-refractory prostate cancer (HRPC) patients with bone metastases. This study assessed the cost effectiveness of ZOL for SRE management in French, German, Portuguese, and Dutch HRPC patients.This analysis was based on the results of a randomized phase III clinical trial wherein HRPC patients received up to 15 months of ZOL (n = 214) or placebo (n = 208). Clinical inputs were obtained from the trial. Costs were estimated using hospital tariffs, published, and internet sources. Quality adjusted life-years (QALYs) gained were estimated from a separate analysis of EQ-5D scores reported in the trial. Uncertainty surrounding outcomes was addressed via univariate sensitivity analyses.ZOL patients experienced an estimated 0.759 fewer SREs and gained an estimated 0.03566 QALYs versus placebo patients. ZOL was associated with reduced SRE-related costs [net costs] (-€2396 [€1284] in France, -€2606 [€841] in Germany, -€3326 [€309] in Portugal and -€3617 [€87] in the Netherlands). Costs per QALY ranged from €2430 (Netherlands) to €36,007 (France).This analysis is subject to the limitations of most cost-effectiveness analyses: it combines data from multiple sources. Nevertheless, the results strongly suggest that ZOL is cost effective versus placebo in French, German, Portuguese, and Dutch HRPC patients." @default.
• W2092114535 created "2016-06-24" @default.
• W2092114535 creator A5055552324 @default.
• W2092114535 creator A5065512022 @default.
• W2092114535 creator A5068637941 @default.
• W2092114535 creator A5087184017 @default.
• W2092114535 date "2011-01-01" @default.
• W2092114535 modified "2023-10-17" @default.
• W2092114535 title "Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands" @default.
• W2092114535 cites W1580691413 @default.
• W2092114535 cites W170508594 @default.
• W2092114535 cites W1967277688 @default.
• W2092114535 cites W1968511145 @default.
• W2092114535 cites W1969967745 @default.
• W2092114535 cites W1982915376 @default.
• W2092114535 cites W1991890714 @default.
• W2092114535 cites W1996589664 @default.
• W2092114535 cites W2006495870 @default.
• W2092114535 cites W2011000634 @default.
• W2092114535 cites W2026500950 @default.
• W2092114535 cites W2029054819 @default.
• W2092114535 cites W2040373783 @default.
• W2092114535 cites W2044365993 @default.
• W2092114535 cites W2062874067 @default.
• W2092114535 cites W2066845679 @default.
• W2092114535 cites W2078899066 @default.
• W2092114535 cites W2084177425 @default.
• W2092114535 cites W2089514388 @default.
• W2092114535 cites W2090892600 @default.
• W2092114535 cites W2104206635 @default.
• W2092114535 cites W2104923745 @default.
• W2092114535 cites W2109361037 @default.
• W2092114535 cites W2109921641 @default.
• W2092114535 cites W2116887796 @default.
• W2092114535 cites W2141884093 @default.
• W2092114535 cites W2142234592 @default.
• W2092114535 cites W2148154473 @default.
• W2092114535 cites W2152409486 @default.
• W2092114535 cites W2159492992 @default.
• W2092114535 cites W2162794236 @default.
• W2092114535 cites W2166707293 @default.
• W2092114535 cites W2607028219 @default.
• W2092114535 cites W3020646939 @default.
• W2092114535 doi "https://doi.org/10.3111/13696998.2011.570170" @default.
• W2092114535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21469915" @default.
• W2092114535 hasPublicationYear "2011" @default.
• W2092114535 type Work @default.
• W2092114535 sameAs 2092114535 @default.
• W2092114535 citedByCount "10" @default.
• W2092114535 countsByYear W20921145352012 @default.
• W2092114535 countsByYear W20921145352013 @default.
• W2092114535 countsByYear W20921145352015 @default.
• W2092114535 countsByYear W20921145352016 @default.
• W2092114535 countsByYear W20921145352017 @default.
• W2092114535 countsByYear W20921145352018 @default.
• W2092114535 countsByYear W20921145352019 @default.
• W2092114535 crossrefType "journal-article" @default.
• W2092114535 hasAuthorship W2092114535A5055552324 @default.
• W2092114535 hasAuthorship W2092114535A5065512022 @default.
• W2092114535 hasAuthorship W2092114535A5068637941 @default.
• W2092114535 hasAuthorship W2092114535A5087184017 @default.
• W2092114535 hasBestOaLocation W20921145351 @default.
• W2092114535 hasConcept C112930515 @default.
• W2092114535 hasConcept C121608353 @default.
• W2092114535 hasConcept C121955636 @default.
• W2092114535 hasConcept C126322002 @default.
• W2092114535 hasConcept C138885662 @default.
• W2092114535 hasConcept C142724271 @default.
• W2092114535 hasConcept C143998085 @default.
• W2092114535 hasConcept C144133560 @default.
• W2092114535 hasConcept C204787440 @default.
• W2092114535 hasConcept C27081682 @default.
• W2092114535 hasConcept C2776326535 @default.
• W2092114535 hasConcept C2780192828 @default.
• W2092114535 hasConcept C29456083 @default.
• W2092114535 hasConcept C3019080777 @default.
• W2092114535 hasConcept C35219183 @default.
• W2092114535 hasConcept C41895202 @default.
• W2092114535 hasConcept C535046627 @default.
• W2092114535 hasConcept C6964187 @default.
• W2092114535 hasConcept C71924100 @default.
• W2092114535 hasConceptScore W2092114535C112930515 @default.
• W2092114535 hasConceptScore W2092114535C121608353 @default.
• W2092114535 hasConceptScore W2092114535C121955636 @default.
• W2092114535 hasConceptScore W2092114535C126322002 @default.
• W2092114535 hasConceptScore W2092114535C138885662 @default.
• W2092114535 hasConceptScore W2092114535C142724271 @default.
• W2092114535 hasConceptScore W2092114535C143998085 @default.
• W2092114535 hasConceptScore W2092114535C144133560 @default.
• W2092114535 hasConceptScore W2092114535C204787440 @default.
• W2092114535 hasConceptScore W2092114535C27081682 @default.
• W2092114535 hasConceptScore W2092114535C2776326535 @default.
• W2092114535 hasConceptScore W2092114535C2780192828 @default.
• W2092114535 hasConceptScore W2092114535C29456083 @default.
• W2092114535 hasConceptScore W2092114535C3019080777 @default.
• W2092114535 hasConceptScore W2092114535C35219183 @default.
• W2092114535 hasConceptScore W2092114535C41895202 @default.
• W2092114535 hasConceptScore W2092114535C535046627 @default.

• next